1291P A phase II study of nivolumab rechallenge therapy in advanced NSCLC patients who responded to prior anti-PD-1/L1 inhibitors: West Japan Oncology Group 9616L

Autor:	Hidetoshi Hayashi, Kazuhiko Nakagawa, Naoki Furuya, Hiroaki Akamatsu, Takeharu Yamanaka, Yoshimasa Shiraishi, Satoru Miura, Akito Hata, Nobuyuki Yamamoto, S. Takamori, Y. Toi, Yuki Sato, Shunsuke Teraoka, N. Mamesaya, Yasuhiro Koh
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty business.industry Internal medicine Anti pd 1 medicine Phases of clinical research Hematology Nivolumab business
Zdroj:	Annals of Oncology. 32:S1001-S1002
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8bba9680f37539f1418fe242763635f3 https://doi.org/10.1016/j.annonc.2021.08.1893 Zobrazit plný text záznamu